Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration
Publication date: Available online 11 April 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Chandrashekhar Dasari, Karthik Reddy Kami Reddy, Sirisha Natani, T.R.L. Murthy, Supriya Bhukya, Ramesh UmmanniAbstractTumor protein D52 (TPD52) is overexpressed in multiple cancers including prostate cancer due to gene amplification and investigations to understand its role in the pathophysiology of different cancers are continuing. GST pull-down assays and Tandem affinity purification of TPD52 as bait identified novel prey Peroxiredoxin 1 (PRDX1) in prostate cancer (PCa) cells. PRDX1 interaction with TPD52 was confirmed in immunoprecipitation and affinity interaction assays. Mapping of interaction domain indicated that PRDX1 interacts with C-terminal region of TPD52 containing PEST domain between 152 and 179 amino acids, a new binding region of TPD52. Here we show that TPD52 interaction with PRDX1 increased its peroxidase activity and ectopic expression of TPD52 induced dimerization of PRDX1 in PCa cells. Moreover, H2O2 exposure evoked the interaction between TPD52 and PRDX1 while depletion of both proteins led to the accumulation of H2O2 suggesting peroxidase activity is important to maintain oxidative capacity in PCa cells. We also observed that overexpression or downregulation of TPD52 and PRDX1 individually or together affecting PCa cells growth, survival, and migration. Altogether, our results show a novel interaction partner of TPD52 providing...
PET imaging with radiotracers to accurately identify molecules in cancer cells...Read more on AuntMinnie.comRelated Reading: PET tracer may aid diagnosis of inflammatory bowel disease Immuno-PET tracer offers hope for early cancer treatment Novel PET tracer could identify bacterial infections Immuno-PET radiotracers may aid cancer treatment Novel PET tracer aids recurrent prostate cancer patients
(American Association for Cancer Research) Inflammatory and immune-regulatory mechanisms were found to be altered in animal models and in archived prostate cancer tumor samples of responders exposed to dust from the World Trade Center terrorist attacks on Sept. 11, 2001.
abine Mai The individual risk to progression is unclear for intermediate risk prostate cancer patients. To assess their risk to progression, we examined the level of genomic instability in circulating tumor cells (CTCs) using quantitative three-dimensional (3D) telomere analysis. Data of CTCs from 65 treatment-naïve patients with biopsy-confirmed D’Amico-defined intermediate risk prostate cancer were compared to radical prostatectomy pathology results, which provided a clinical endpoint to the study and confirmed pre-operative pathology or demonstrated upgrading. Hierarchical centroid cluster analysi...
ConclusionsSPT produces a durable response in AR-pathway inhibitor ENZ CRPC that is associated with sustained suppression of ARv7 and E2F transcriptional outputs, and the DDR transcriptome, highlighting the potential of combination treatments that maintain suppression of these programs to drive a durable response to SPT.Patient summaryPatients with ENZ-resistant prostate cancer have very limited treatment options. Supraphysiological testosterone presents a prominent option for improved quality of life and a potential durable response in patients with sustained suppression on ARv7/E2F transcriptional outputs and DNA repair program.
Publication date: Available online 18 June 2019Source: The LancetAuthor(s): Charles Catton, Himu Lukka
Publication date: Available online 18 June 2019Source: The LancetAuthor(s): Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, Camilla Thellenberg-Karlsson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, Mihajl Seke, Måns Agrup, Per Fransson, Björn Tavelin, David Norman, Björn Zackrisson, Harald Anderson, Elisabeth Kjellén, Lars Franzén, Per NilssonSummaryBackgroundHypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies compar...
In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
The practice of prostate radiotherapy is evolving rapidly while there is an increase in the incidence of prostate cancer in India. Here, the diverse socioeconomic milieu and varied healthcare delivery models interact to exert a significant influence on the adoption of new technologies and evidence emerging from the Western world. Using a targeted cross-country survey of radiation oncologists, this article captures the changing trends in prostate imaging, conformal techniques, dose escalation, hypofractionation, stereotactic ablation and prostate brachytherapy in the context of practice patterns in the West.